Studies of diagnostic biomarkers have compared PCa patients with healthy individuals, but also to patients afflicted with benign prostate hyperplasia (BPH), which is also usually related to an increased serum PSA level. This evidence concerns the gene PROS1 and benign prostatic hyperplasia.